Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - FENNEC PHARMACEUTICALS INC. | tm2029552d1_ex99-1.htm |
| EX-31.2 - EXHIBIT 31.2 - FENNEC PHARMACEUTICALS INC. | tm2029552d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - FENNEC PHARMACEUTICALS INC. | tm2029552d1_ex31-1.htm |
| 10-Q - FORM 10-Q - FENNEC PHARMACEUTICALS INC. | tm2029552d1_10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Fennec Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020 (the “Report”), each of the undersigned, Rostislav Raykov, Chief Executive Officer of the Company, and Robert Andrade, Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 16, 2020
| By: | /s/ Rostislav Raykov | |
| Rostislav Raykov | ||
| Chief Executive Officer |
Date: November 16, 2020
| By: | /s/ Robert Andrade | |
| Robert Andrade | ||
| Chief Financial Officer |